0001628280-19-015076.txt : 20191213
0001628280-19-015076.hdr.sgml : 20191213
20191213161208
ACCESSION NUMBER: 0001628280-19-015076
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20191213
FILED AS OF DATE: 20191213
DATE AS OF CHANGE: 20191213
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Maslowski John Michael
CENTRAL INDEX KEY: 0001608774
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-31564
FILM NUMBER: 191284737
MAIL ADDRESS:
STREET 1: 404 EAGLEVIEW BOULEVARD
CITY: EXTON
STATE: PA
ZIP: 19341
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Fibrocell Science, Inc.
CENTRAL INDEX KEY: 0000357097
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 870458888
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 405 EAGLEVIEW BOULEVARD
CITY: EXTON
STATE: PA
ZIP: 19341
BUSINESS PHONE: 484-713-6000
MAIL ADDRESS:
STREET 1: 405 EAGLEVIEW BOULEVARD
CITY: EXTON
STATE: PA
ZIP: 19341
FORMER COMPANY:
FORMER CONFORMED NAME: ISOLAGEN INC
DATE OF NAME CHANGE: 20020320
FORMER COMPANY:
FORMER CONFORMED NAME: AMERICAN FINANCIAL HOLDING INC /DE
DATE OF NAME CHANGE: 19960330
FORMER COMPANY:
FORMER CONFORMED NAME: AMERICAN FINANCIAL HOLDING INC /CO
DATE OF NAME CHANGE: 19921008
4
1
wf-form4_157627151073429.xml
FORM 4
X0306
4
2019-12-13
1
0000357097
Fibrocell Science, Inc.
FCSC
0001608774
Maslowski John Michael
FIBROCELL SCIENCE, INC.
405 EAGLEVIEW BOULEVARD
EXTON
PA
19341
1
1
0
0
CEO
Common Stock
2019-12-13
4
D
0
3164
3
D
0
D
Option to Purchase Common Stock
232.5
2019-12-13
4
D
0
908
D
2021-01-14
Common Stock
908.0
0
D
Option to Purchase Common Stock
82.35
2019-12-13
4
D
0
1167
D
2023-07-19
Common Stock
1167.0
0
D
Option to Purchase Common Stock
74.25
2019-12-13
4
D
0
1334
D
2024-01-17
Common Stock
1334.0
0
D
Option to Purchase Common Stock
44.1
2019-12-13
4
D
0
1334
D
2024-05-13
Common Stock
1334.0
0
D
Option to Purchase Common Stock
52.95
2019-12-13
4
D
0
6668
D
2025-01-20
Common Stock
6668.0
0
D
Option to Purchase Common Stock
34.05
2019-12-13
4
D
0
6667
D
2026-03-01
Common Stock
6667.0
0
D
Option to Purchase Common Stock
9.94
2019-12-13
4
D
0
16667
D
2026-12-16
Common Stock
16667.0
0
D
Option to Purchase Common Stock
3.45
2019-12-13
4
D
0
20000
D
2028-01-25
Common Stock
20000.0
0
D
Option to Purchase Common Stock
1.78
2019-12-13
4
D
0
100000
D
2029-04-12
Common Stock
100000.0
0
D
Pursuant to the Agreement and Plan of Merger, dated as of September 12, 2019 (the "Merger Agreement"), among Fibrocell Science, Inc. (the "Company"), Castle Creek Pharmaceutical Holdings, Inc. and Castle Creek Merger Corp., effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, these shares of Company common stock were converted into the right to receive a cash payment equal to the per share merger consideration of $3.00.
Pursuant to the Merger Agreement, effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, outstanding options, whether vested or not, became fully vested in accordance with the terms of the Merger Agreement and were canceled in exchange for a cash payment equal to the number of shares of Company common stock underlying the options multiplied by the excess of the per share merger consideration of $3.00 over the per share exercise price.
/s/ John M. Maslowski
2019-12-13